logo
logo

CANbridge Pharmaceuticals Completes US$98 Million Series D Financing

Feb 18, 2020•over 5 years ago

Amount Raised

$98 Million

Round Type

series d

Beijing

Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced the completion of a US$98 million Series D financing. The round was led by General Atlantic, a leading global growth equity firm, and WuXi AppTec. Each firm also has the option to invest up to an additional $10 million, upon the satisfaction of certain conditions by CANbridge. Additional participating investors in this round include RA Capital Management, Hudson Bay Capital Management, YuanMing Prudence Fund and Tigermed

Company Information

Company

Ca Nbridge Pharmaceuticals

Location

Beijing, Beijing, China

About

CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech